Cancer Australia

Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein

Retrieved on: 
星期一, 一月 15, 2024
National Comprehensive Cancer Network, Patient, Prostate cancer, Health, Attention, Palliative care, Cancer Australia, Breast cancer, ESMO, Cancer, Scalp, Quality of life, NCCN, FDA, Hair loss, Breast, Prostate, Oncology

LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.

Key Points: 
  • LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.
  • Switzerland is a strong market for scalp cooling with many options for quality private healthcare in addition to the public sector clinics.
  • The distribution agreement with OncoMedical seeks to expand that footprint in Switzerland and Liechtenstein, while also upgrading current Dignitana customers to the advanced technology offered by the next generation DigniCap Delta system.
  • "OncoMedical shares our commitment to excellence in technology, customer service and patient care," said Catarina Löwenadler, CEO of Dignitana.

Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States

Retrieved on: 
星期三, 十月 4, 2023
Partnership, Society, Cancer Australia, Hair loss, Marketing, ESMO, Breast, National Comprehensive Cancer Network, Oncology, Scalp, NCCN, Patient, Growth, European Society for Medical Oncology, FDA, Pharmaceutical industry

LUND, Sweden, Oct. 4, 2023 /PRNewswire/ -- Scalp cooling innovator Dignitana AB announces today a sales and marketing partnership with InfuSystem Holdings, Inc., a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers in the United States.

Key Points: 
  • LUND, Sweden, Oct. 4, 2023 /PRNewswire/ -- Scalp cooling innovator Dignitana AB announces today a sales and marketing partnership with InfuSystem Holdings, Inc., a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers in the United States.
  • This partnership is a significant step forward as Dignitana continues to accelerate growth in our most important market, and make scalp cooling available to as many patients as possible."
  • Carrie Lachance, President and COO of InfuSystem, said, "We are pleased to partner with Dignitana to provide our customers with access to DigniCap Scalp Cooling System, a premium solution for chemotherapy-induced alopecia.
  • The FDA-cleared DigniCap Scalp Cooling System is clinically proven to minimize hair loss from chemotherapy for cancer patients with solid tumors such as breast, ovarian and prostate cancer.

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Retrieved on: 
星期一, 九月 11, 2023
Cancer, MRFF, University, Royal Melbourne Hospital, Cancer Australia, Bureau of Oceans and International Environmental and Scientific Affairs, National Guideline Clearinghouse, GTG, The Royal Marsden NHS Foundation Trust, Risk, University of Melbourne, Policy, ASX, Breast, Research, Genomics, Prostate, History, Queen Mary University of London, General practice, Standard of care, Melanoma, Genetypes, Scores, Biostatistics, Health, Medical Research Future Fund, Primary care, Pharmaceutical industry, Vaccine

The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

Key Points: 
  • The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.
  • GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
  • The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
  • As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.

Brain Cancer Diagnostics Market Report 2022: Increase in Brain Cancer and Cigarette Smokers Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 13, 2022
Health, Oncology, Medical Devices, Incidence, COVID-19, Brain, Prevalence, Cancer Research UK, Glioblastoma, CM3, Neoplasm, Meningioma, MRI, SES Platform Services, Growth, American Association, Nuclear magnetic resonance spectroscopy, Ganglioneuroma, PET, Cancer, American Association of Neurological Surgeons, Solution, CT, Ependymoma, Congress of Neurological Surgeons, Craniopharyngioma, Cancer Australia, CNS, H. Lee Moffitt Cancer Center & Research Institute, Astrocytoma, Ageing, Association, EEG, Hospital, Oligodendroglioma, Biopsy, Electroencephalography, MRS, CAGR, Medical imaging

The global brain cancer diagnostics market is expected to grow from US$ 1,639.10 million in 2022 to US$ 7,378.57 million by 2028.

Key Points: 
  • The global brain cancer diagnostics market is expected to grow from US$ 1,639.10 million in 2022 to US$ 7,378.57 million by 2028.
  • The increase in brain cancer worldwide and the rise in cigarette smokers boost the growth of the global brain cancer diagnostics market.
  • Thus, the increase in the prevalence of brain cancer worldwide highly demands brain cancer diagnostic tools.
  • Based on cancer type, the brain cancer diagnostics market is segmented into acoustic neuroma, astrocytomas, craniopharyngiomas, ganglioneuromas, glioblastoma multiforme, ganglioneuroma, meningiomas, ependymomas, oligodendroglioma, low-grade tumors, and others.